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Forest Plot for the Effect of Dabigatran Versus Control on
Incident MI
CI ¼ conﬁdence interval; MI ¼ myocardial infarction; RE-COVER ¼ Dabigatran
versus Warfarin in the Treatment of Acute Venous Thromboembolism; RE-DEEM ¼
RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute
Coronary Syndromes Post Index Event With Additional Risk Factors for Cardio-
vascular Complications Also Receiving Aspirin and Clopidogrel: Multi-centre,
Prospective, Placebo Controlled, Cohort Dose Escalation Study; RE-LY ¼
Randomized Evaluation of Long-Term Anticoagulation Therapy; RE-MEDY ¼ A
Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled
Study to Evaluate the Efﬁcacy and Safety of Oral Dabigatran Etexilate (150 mg bid)
Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous
Thromboembolism; RE-SONATE ¼ Twice-daily Oral Direct Thrombin Inhibitor
Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic
Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein
Thrombosis or Pulmonary Embolism.Dabigatran’s ‘Real-World’ Data
About Risk of Myocardial
Infarction and Gastrointestinal
Bleeding Contradicts With
Randomized Trials
We read with great interest the article by Larsen et al. (1) examining
the safety of dabigatran, especially with regard to myocardial
infarction (MI) and gastrointestinal bleeding using Danish national
databases. They report a remarkable, highly signiﬁcant 60% to 70%
risk reduction in MIs with dabigatran as compared with warfarin
(p < 0.0001). Similarly, they report a 40% reduction in incident
gastrointestinal bleeding with 110 mg dabigatran twice daily
compared with warfarin, which was again statistically signiﬁcant.
While examination of observational administrative datasets may
sometimes be helpful to answer certain questions, the gold standard
for determining drug safety and efﬁcacy is careful analysis of allavailable randomized controlled clinical trials. With regard to MI,
several randomized trials have reported data with dabigatran. All of
these studies (except the RE-SONATE [Twice-daily Oral Direct
Thrombin Inhibitor Dabigatran Etexilate in the Long-term
Prevention of Recurrent Symptomatic Proximal Venous Throm-
boembolism in Patients With Symptomatic Deep-vein Thrombosis
or Pulmonary Embolism] trial with only single events in each arm)
showed a numerical excess in MIs with dabigatran (2–6).
Combined analysis of all these trials shows a 48% increase in MIs
with dabigatran as compared to controls (p ¼ 0.005) (Fig. 1).
Removal of any single study, including the RE-LY (Randomized
Evaluation of Long-Term Anticoagulation Therapy) trial (3) that
generated the hypothesis that dabigatran increases risk of MI, does
not change the statistically signiﬁcant excess in MIs. On the other
hand, regarding the gastrointestinal bleeding risk, the RE-LY trial
reported this event in 10% of patients receiving dabigatran 110 mg
twice daily and in 7.5% of patients receiving warfarin (p < 0.00001
for dabigatran vs. warfarin) (2). In this trial the excess in gastro-
intestinal bleeding events was even more pronounced for dabigatran
150 mg twice daily compared with warfarin. The RE-COVER
(Dabigatran versus Warfarin in the Treatment of Acute Venous
Thromboembolism) trial also showed an excess in gastrointestinal
bleeding with dabigatran as compared with warfarin (4.2% vs.
2.8%) (5). Therefore, the results of both the Larsen et al. (1) current
observational study and the randomized controlled clinical trials
show signiﬁcant differences in MI and gastrointestinal bleeding
rates with dabigatran versus warfarin, but in completely opposite
directions. We think that the imperfect nature of observational
studies mostly stemming from residual confounding despite
propensity matching may explain the discrepancy between the
current observational study and previous randomized trials. Can the
authors provide their perspective on the risk of residual con-
founding in their analysis?
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368:709–18.ReplyDabigatran’s ‘Real-World’ Data About
Risk of Myocardial Infarction and
Gastrointestinal Bleeding Contradicts
With Randomized Trials
Dr. Sipahi and colleagues express concern about the discrepancy of
our observational study with randomized controlled studies, and
point to residual confounding as a possible explanation. We have
already discussed these issues in the paper (1), but will expand on
our discussion in the following paragraph.
In observational studies of intended drug effects or safety,
substantial confounding (by indication) is to be expected because
the perceived risk is often closely related to the physician’s choice
of treatment (2). Where there is confounding, there is also the
possibility of residual confounding. Taken to the extreme, hetero-
geneity in risk factors (measured or unmeasured) between treat-
ment groups in key risk factors is a possible explanation for the
observed associations. However, “possible” need not mean “plau-
sible.” Indeed, a careful choice of methods and principles can
mitigate confounding concerns in observational studies (3).
In our study, we adopted a new-user design to ensure that mean-
ingful comparisons were made (4). We explored both propensity
score matching and regression-based confounder adjustment and
found no appreciable differences between these approaches. Last, wefound reassurance in the fact that estimates changed only modestly
upon adjustment for key risk factors for the outcome. Any unmea-
sured confounders would have to be very strongly associated with
treatment and outcome in order for estimates and conclusions to
change qualitatively (5). While it is possible that such unmeasured
confounders exist, we do not consider it very plausible.
There can be other explanations for the discrepancies between
observational and randomized studies (6), which seem more
plausible here. For example, differences in length of follow-up
may result in different conclusions. Also, randomized controlled
trials are externally valid only for the type of patients included in
that trial. Our observational study represents a “real world” pop-
ulation, in which patients had a lower stroke risk cohort compared
with the RE-LY (Randomized Evaluation of Long-Term Anti-
coagulation Therapy) trial (7) participants (mean CHADS2 scores
of 1.2 and 2.1, respectively), and correspondingly, a lower
myocardial infarction risk as well. Also, our patients had a lower
prevalence of prior myocardial infarction or fewer risk factors for
the same (e.g., diabetes mellitus, hypertension), compared with
the RE-LY trial.
In their letter, Sipahi et al. proclaim randomized trials as the gold
standard for drug efﬁcacy and safety assessments. While random-
ized controlled trials are indeed the gold standard in the sense of
providing “fair” comparisons, they may not always provide the most
relevant comparisons. Well-designed observational studies can
address the question whether drug treatment works in daily clinical
practice, not just whether the drug by itself works in ideal settings.
Careful consideration of all the available evidence (randomized and
observational) should be considered the gold standard for post-
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